Cutaneous lupus erythematosus (overview) L93.-

Author: Prof. Dr. med. Peter Altmeyer

Our authors

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

CLE; Cutaneous lupus erythematosus; Hautlupus; Lupus erythematosus integumentalis; Lupus erythematosus of the skin

Definition
This section has been translated automatically.

Cutaneous lupus erythematosus (CL) is an acute, sub-acute or chronic inflammatory autoimmune disease dominated by skin symptoms with a broad spectrum of clinical manifestations and a variable course. Depending on the acuteity and depth of the infiltrate cells, different subtypes can be distinguished. Important: Transitional forms are observed as well as the synchronous occurrence of several subtypes in one individual.

Classification
This section has been translated automatically.

A general classification of cutaneous lupus erythematosus (CLE) goes back to Gilliam and Sontheimer (1981), which distinguishes between specific and non-specific lesions of the cutaneous LE. The course of the disease can be divided into three groups according to acuity. Accordingly, a distinction is made between:

  • Acute
  • Subacute
  • Chronic

The following clearly defined clinical clinical pictures are classified in these categories. The numbers in brackets refer to their frequency within a collective of CL patients (Biazar C et al. 2013):

Occurrence/Epidemiology
This section has been translated automatically.

Worldwide occurrence; the incidence of cutaneous lupus erythematosus is about 10 times higher than that of systemic lupus erythematosus (SLE).

Etiopathogenesis
This section has been translated automatically.

It is assumed that in cutaneous LE (CLE) epidermal keratinocytes are the target cell of the "immunological injury". It is postulated that an autoimmunological reaction is triggered by increased apoptosis induction (keratinocytes of LE patients produce increased IL-18 receptors on their surface after stimulation with TNF-α or IFN-γ; they become more apoptotic after IL-18 exposure. At the same time, the production of IL-12 is reduced; IL-12 protects keratinocytes from UV-induced apoptosis).

Manifestation
This section has been translated automatically.

Mainly occurring in middle-aged adults (25 - 60 years, mean: 43+/- 16 years), more frequent in women (w:m=3-6:1)

Clinical features
This section has been translated automatically.

See below the individual clinical forms.

Laboratory
This section has been translated automatically.

Rarely antinuclear factors or cardiolipin antibodies, leukopenia ( autoantibodies).

Histology
This section has been translated automatically.

See below the individual clinical forms.

Complication(s)
This section has been translated automatically.

Mutilations, irreversible alopecia, poorly healing ulcerations with development of spinocellular carcinomas, among others, can occur.

Therapy
This section has been translated automatically.

According to the lupus erythematodes chronicus discoides and the individual clinical variants, see there.

Progression/forecast
This section has been translated automatically.

Chronic course over years, defect healing. In about 5% transition to systemic lupus erythematosus.

Tables
This section has been translated automatically.

Clinical forms of integumentary lupus erythematosus

Lupus erythematosus discoides

Lupus erythematodes chronicus integumentalis cum exacerbatione acuta

Lupus erythematodes chronicus superficiales disseminatus

Lupus erythematosus profundus

Lupus erythematosus hypertrophicus et profundus

Lupus erythematosus verrucosus

lupus erythematosus tumidus

Chilblain Lupus

Diet/life habits
This section has been translated automatically.

In all forms of lupus erythematosus, increased sensitivity to both UVB and UVA (less frequently to visible light) is found. Strict light protection is therefore necessary. After UV provocation, the reactions mostly occur after one week or later.

Note(s)
This section has been translated automatically.

For clinical studies, some authors propose the "Cutaneous Lupus Erythematodes Disease Area and Severity Index" (CLASI), which considers localization, erythema, scaling and infiltration, dyspigmentation and scarring.

Literature
This section has been translated automatically.

  1. Albrecht J et al (2005) The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythemtosus. J Invest Dermatol 125: 889-894
  2. Biazar C et al (2013) EUSCLE co-authors. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmune Rev 12:444-454
  3. Bohmeyer J et al (2002) Thalidomide therapy of cutaneous lupus erythematosus. dermatologist 53: 744-748
  4. Fabbri P et al (2003) Cutaneous lupus erythematosus: diagnosis and management. At J Clin Dermatol 4: 449-465
  5. Gilliam JN, Sontheimer RD (1981) Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 4: 471-475
  6. Kind P et al (1992) Cutaneous lupus erythematosus and cardiolipin antibodies. dermatologist 43: 126-129
  7. Kuhn A et al (2000) Rare cutaneous manifestations of lupus erythematosus. A clinical overview. dermatologist 51: 818-825
  8. Sander CJG (2003) Phtosensitivity in patients wiith lupus erythematosus: a clinical and photobiological study in 100 patients using a prolonged phototest protocol. Br J Dermatol 149: 131-137
  9. Wang D et al (2008) Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum 58: 3205-3215

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 29.10.2020